Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 21.68 | 0.09% | 0.02 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ICPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.09% | |
| Lower Bollinger Band Walk | Weakness | 0.09% | |
| New 52 Week Low | Weakness | 0.09% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Fell Below Previous Day's Low | about 5 hours ago | |
| New 52 Week Low | about 5 hours ago | |
| 60 Minute Opening Range Breakdown | about 5 hours ago | |
| Rose Above Lower Bollinger Band | about 10 hours ago | |
| Up 3% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/23/2021
Intercept Pharmaceuticals, Inc. Description
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Liver Disease Hepatology Diarrhea Fibrosis Liver Diseases Bile Acid Digestive Diseases Chronic Liver Disease Chronic Liver Diseases Cirrhosis Primary Biliary Cholangitis Farnesoid X Receptor Fxr Obeticholic Acid
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 98.03 |
| 52 Week Low | 21.45 |
| Average Volume | 1,121,757 |
| 200-Day Moving Average | 44.15 |
| 50-Day Moving Average | 30.29 |
| 20-Day Moving Average | 31.35 |
| 10-Day Moving Average | 27.84 |
| Average True Range | 2.38 |
| ADX | 32.09 |
| +DI | 8.98 |
| -DI | 35.74 |
| Chandelier Exit (Long, 3 ATRs ) | 31.28 |
| Chandelier Exit (Short, 3 ATRs ) | 28.60 |
| Upper Bollinger Band | 40.68 |
| Lower Bollinger Band | 22.02 |
| Percent B (%b) | -0.02 |
| BandWidth | 59.50 |
| MACD Line | -2.28 |
| MACD Signal Line | -0.90 |
| MACD Histogram | -1.3838 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.48 | ||||
| Resistance 3 (R3) | 23.60 | 23.13 | 23.18 | ||
| Resistance 2 (R2) | 23.13 | 22.67 | 23.07 | 23.08 | |
| Resistance 1 (R1) | 22.40 | 22.39 | 22.17 | 22.28 | 22.98 |
| Pivot Point | 21.93 | 21.93 | 21.81 | 21.87 | 21.93 |
| Support 1 (S1) | 21.20 | 21.47 | 20.97 | 21.08 | 20.38 |
| Support 2 (S2) | 20.73 | 21.19 | 20.67 | 20.28 | |
| Support 3 (S3) | 20.00 | 20.73 | 20.18 | ||
| Support 4 (S4) | 19.88 |
